Related references
Note: Only part of the references are listed.Aerodynamics Effect of Holes in UAV Wings Modified for VTOL Capability
Laith S. Sawaqed et al.
DRONE SYSTEMS AND APPLICATIONS (2022)
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodies
Thomas Van Blarcom et al.
MABS (2018)
Isolation of blood-brain barrier-crossing antibodies from a phage display library by competitive elution and their ability to penetrate the central nervous system
George Thom et al.
MABS (2018)
Potent and conditional redirected T cell killing of tumor cells using Half DVD-Ig
Philip D. Bardwell et al.
PROTEIN & CELL (2018)
IgG Fc engineering to modulate antibody effector functions
Xinhua Wang et al.
PROTEIN & CELL (2018)
ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy
Seandean Lykke Harwood et al.
ONCOIMMUNOLOGY (2018)
CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy
Bingyu Li et al.
ONCOIMMUNOLOGY (2018)
Bispecific Antibody Process Development: Assembly and Purification of Knob and Hole Bispecific Antibodies
Glen Giese et al.
BIOTECHNOLOGY PROGRESS (2018)
Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity
Andrew D. Tustian et al.
BIOTECHNOLOGY PROGRESS (2018)
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway
Todd Bartkowiak et al.
CLINICAL CANCER RESEARCH (2018)
CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2018)
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
Julius Strauss et al.
CLINICAL CANCER RESEARCH (2018)
Therapeutic bispecific antibody formats: a patent applications review (1994-2017)
Marie Godar et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2018)
Preliminary biomarker and pharmacodynamic data from a phase I study of single-agent bispecific antibody T-cell engager GBR 1302 in subjects with HER2-positive cancers.
Martin Wermke et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Development of MGD007, a gpA33 x CD3-Bispecific DART Protein for T-Cell Immunotherapy of Metastatic Colorectal Cancer
Paul A. Moore et al.
MOLECULAR CANCER THERAPEUTICS (2018)
T cell engaging bispecific antibody (T-BsAb): From technology to therapeutics
Z. Wu et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF beta enhance the efficacy of cancer immunotherapy
Rajani Ravi et al.
NATURE COMMUNICATIONS (2018)
Cell-type specific potent Wnt signaling blockade by bispecific antibody
Nam-Kyung Lee et al.
SCIENTIFIC REPORTS (2018)
Brain Shuttle Antibody for Alzheimer's Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode
Felix Weber et al.
CELL REPORTS (2018)
M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine
Karin M. Knudson et al.
ONCOIMMUNOLOGY (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Beyond binding: antibody effector functions in infectious diseases
Lenette L. Lu et al.
NATURE REVIEWS IMMUNOLOGY (2018)
A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia
Sayed Shahabuddin Hoseini et al.
BLOOD ADVANCES (2018)
Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments
Timothy J. Egan et al.
MABS (2017)
Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells
Michael Dillon et al.
MABS (2017)
Fc-mediated activity of EGFR x c-Met bispecific antibody JNJ-61186372 enhanced killing of lung cancer cells
Katharine D. Grugan et al.
MABS (2017)
Targeted Fcγ Receptor (FcγR)-mediated Clearance by a Biparatopic Bispecific Antibody
Srinath Kasturirangan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1
Camilla De Nardis et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Targeting Anti-TGF-β Therapy to Fibrotic Kidneys with a Dual Specificity Antibody Approach
Steve McGaraughty et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study
Nico van Zandwijk et al.
LANCET ONCOLOGY (2017)
The making of bispecific antibodies
Ulrich Brinkmann et al.
MABS (2017)
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs
Julian Andreev et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Brain and Organ Uptake in the Rhesus Monkey in Vivo of Recombinant Iduronidase Compared to an Insulin Receptor Antibody-Iduronidase Fusion Protein
Ruben J. Boado et al.
MOLECULAR PHARMACEUTICS (2017)
Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study
S. X. Wang et al.
OSTEOARTHRITIS AND CARTILAGE (2017)
A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6
Remy Robert et al.
PLOS ONE (2017)
Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells
Thorsten Gantke et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2017)
Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
Ling Xu et al.
SCIENCE (2017)
Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies
Constantinos Petrovas et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Monoclonal antibodies: A review of therapeutic applications and future prospects
Aliyu Mahmuda et al.
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH (2017)
Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy
Yu-Cheng Su et al.
NATURE COMMUNICATIONS (2017)
Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor
Greta Hultqvist et al.
THERANOSTICS (2017)
In Vitro Maturation of a humanized shark Vnar Domain to improve its Biophysical Properties to Facilitate clinical Development
John Steven et al.
FRONTIERS IN IMMUNOLOGY (2017)
VHH-Based Bispecific Antibodies Targeting Cytokine Production
Maxim A. Nosenko et al.
FRONTIERS IN IMMUNOLOGY (2017)
Camelid Single-Domain Antibodies: Historical Perspective and Future Outlook
Mehdi Arbabi-Ghahroudi
FRONTIERS IN IMMUNOLOGY (2017)
Stability-Diversity Tradeoffs Impose Fundamental Constraints on Selection of Synthetic Human VH/VL Single-Domain Antibodies from In Vitro Display Libraries
Kevin A. Henry et al.
FRONTIERS IN IMMUNOLOGY (2017)
Determinants of the assembly and function of antibody variable domains
Eva Maria Herold et al.
SCIENTIFIC REPORTS (2017)
Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology
William M. Pardridge
BIODRUGS (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Camelid and shark single domain antibodies: structural features and therapeutic potential
Doreen Koenning et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2017)
A novel tumor-targeted 4-1BB agonist and its combination with T-cell bispecific antibodies: an off-the-shelf cancer immunotherapy alternative to CAR T-cells
Christina Claus et al.
CANCER RESEARCH (2017)
Delivery of a CD20 transferrin receptor VNAR bispecific antibody to the brain for CNS lymphoma
Frank S. Walsh et al.
CANCER RESEARCH (2017)
AMX-168, a long-acting, tumor protease-sensitive bispecific precursor for the treatment of solid malignancies
Bee-Cheng Sim
CANCER RESEARCH (2017)
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing
Ji Li et al.
CANCER CELL (2017)
A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
Naoki Uchida et al.
BLOOD (2016)
Single-domain antibodies for biomedical applications
Simon Krah et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2016)
Characterization of Chain Pairing Variants of Bispecific IgG Expressed in a Single Host Cell by High-Resolution Native and Denaturing Mass Spectrometry
Luis Schachner et al.
ANALYTICAL CHEMISTRY (2016)
Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature
David Kavanagh et al.
BLOOD (2016)
Single domain antibody-based bispecific antibody induces potent specific anti-tumor activity
Jing Li et al.
CANCER BIOLOGY & THERAPY (2016)
ABiparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
John Y. Li et al.
CANCER CELL (2016)
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors
Sheri L. Moores et al.
CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases
Joerg T. Regula et al.
EMBO MOLECULAR MEDICINE (2016)
Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and TIL expansion in a humanized mouse model
M. J. Hinner et al.
EUROPEAN JOURNAL OF CANCER (2016)
Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies
William M. Pardridge
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site
Jonathan D. Kiefer et al.
IMMUNOLOGICAL REVIEWS (2016)
Pharmacokinetics and Tolerability of a Dual Variable Domain Immunoglobulin ABT-981 Against IL-1 and IL-1 in Healthy Subjects and Patients With Osteoarthritis of the Knee
Matthew P. Kosloski et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2016)
CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy
Katelyn T. Byrne et al.
JOURNAL OF IMMUNOLOGY (2016)
Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies
Josee Golay et al.
JOURNAL OF IMMUNOLOGY (2016)
Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody
Sherri Dudal et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Anti-tumoral, anti-angiogenic and anti-metastatic efficacy of a tetravalent bispecific antibody (TAvi6) targeting VEGF-A and angiopoietin-2
Werner Scheuer et al.
MABS (2016)
An efficient route to bispecific antibody production using single-reactor mammalian co-culture
Whitney Shatz et al.
MABS (2016)
Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity
Andrew D. Tustian et al.
MABS (2016)
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications
Anke Steinmetz et al.
MABS (2016)
A bispecific antibody effectively neutralizes all four serotypes of dengue virus by simultaneous blocking virus attachment and fusion
Xin Shi et al.
MABS (2016)
Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis
Dongheon Lee et al.
MABS (2016)
The use of CrossMAb technology for the generation of bi- and multispecific antibodies
Christian Klein et al.
MABS (2016)
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Peter Brunker et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Cell-type-restricted anti-cytokine therapy: TNF inhibition from one pathogenic source
Grigory A. Efimov et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
A Trojan horse bispecific-antibody strategy for broad protection against ebolaviruses
Anna Z. Wec et al.
SCIENCE (2016)
Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation
Welbeck Danquah et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Computationally Designed Bispecific Antibodies using Negative State Repertoires
Andrew Leaver-Fay et al.
STRUCTURE (2016)
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
Rob N. de Jong et al.
PLOS BIOLOGY (2016)
Clinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adults
Kum Ja Lee et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2016)
Mono- and dual-targeting triplebodies activate natural killer cells and have anti-tumor activity in vitro and in vivo against chronic lymphocytic leukemia
Maulik Vyas et al.
ONCOIMMUNOLOGY (2016)
CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors
Marina Bacac et al.
ONCOIMMUNOLOGY (2016)
Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model
Jennifer A. MacDiarmid et al.
PLOS ONE (2016)
A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis
Youngkyun Kim et al.
SCIENTIFIC REPORTS (2016)
Development of PF-06671008, a Highly Potent Anti-P-cadherin/Anti-CD3 Bispecific DART Molecule with Extended Half-Life for the Treatment of Cancer
Adam R. Root et al.
ANTIBODIES (2016)
Improved assembly of bispecific antibodies from knob and hole half-antibodies
Ambrose Jon Williams et al.
BIOTECHNOLOGY PROGRESS (2015)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008)
Mario E. Lacouture et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety
Said C. Azoury et al.
CURRENT CANCER DRUG TARGETS (2015)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
Challenges and opportunities for non-antibody scaffold drugs
Rodrigo Vazquez-Lombardi et al.
DRUG DISCOVERY TODAY (2015)
Infection risk associated with anti-TNF-α agents: a review
Giuseppe Murdaca et al.
EXPERT OPINION ON DRUG SAFETY (2015)
A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism
Zhi Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin
Michal Pyzik et al.
JOURNAL OF IMMUNOLOGY (2015)
Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach
Andreas Lehmann et al.
MABS (2015)
Fab-based bispecific antibody formats with robust biophysical properties and biological activity
Xiufeng Wu et al.
MABS (2015)
Improving target cell specificity using a novel monovalent bispecific IgG design
Yariv Mazor et al.
MABS (2015)
Mechanisms of action of therapeutic antibodies for cancer
J. M. Redman et al.
MOLECULAR IMMUNOLOGY (2015)
Alternative molecular formats and therapeutic applications for bispecific antibodies
Christoph Spiess et al.
MOLECULAR IMMUNOLOGY (2015)
Characterization of a Bispecific FLT3 X CD3 Antibody in an Improved, Recombinant Format for the Treatment of Leukemia
Michael Durben et al.
MOLECULAR THERAPY (2015)
Receptor Crosslinking: A General Method to Trigger Internalization and Lysosomal Targeting of Therapeutic Receptor:Ligand Complexes
Paul R. Moody et al.
MOLECULAR THERAPY (2015)
Targeting the TGFβ pathway for cancer therapy
Cindy Neuzillet et al.
PHARMACOLOGY & THERAPEUTICS (2015)
Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies
Liping L. Sun et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG
Nicolas Fischer et al.
NATURE COMMUNICATIONS (2015)
A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
Eric J. Smith et al.
SCIENTIFIC REPORTS (2015)
Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells
Derek D. Sloan et al.
PLOS PATHOGENS (2015)
Antibody-based strategies to prevent and treat influenza
Zachary Shriver et al.
FRONTIERS IN IMMUNOLOGY (2015)
Sustained Brown Fat Stimulation and Insulin Sensitization by a Humanized Bispecific Antibody Agonist for Fibroblast Growth Factor Receptor 1/βKlotho Complex
Ganesh Kolumam et al.
EBIOMEDICINE (2015)
Blood-brain barrier drug delivery of IgG fusion proteins with a transferrin receptor monoclonal antibody
William M. Pardridge
EXPERT OPINION ON DRUG DELIVERY (2015)
A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells
Benjamin J. Solomon et al.
PLOS ONE (2015)
Combined Inhibition of Tumor Necrosis Factor α and Interleukin-17 As a Therapeutic Opportunity in Rheumatoid Arthritis Development and Characterization of a Novel Bispecific Antibody
Jens A. A. Fischer et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Mutational approaches to improve the biophysical properties of human single-domain antibodies
Dae Young Kim et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
A new bispecific antibody targeting non-overlapping epitopes on IGF2: Design, in vitro characterization and pharmacokinetics in macaques
Yang Feng et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2014)
A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties
Juergen M. Schanzer et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants
Nga Bien-Ly et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Immunogenicity of therapeutic proteins: Influence of aggregation
Kirsty D. Ratanji et al.
JOURNAL OF IMMUNOTOXICOLOGY (2014)
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface
Steven M. Lewis et al.
NATURE BIOTECHNOLOGY (2014)
Controlled Fab-arm exchange for the generation of stable bispecific IgG1
Aran F. Labrijn et al.
NATURE PROTOCOLS (2014)
Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle
Jens Niewoehner et al.
NEURON (2014)
Complement Is Activated by IgG Hexamers Assembled at the Cell Surface
Christoph A. Diebolder et al.
SCIENCE (2014)
A multifunctional bispecific antibody protects against Pseudomonas aeruginosa
Antonio DiGiandomenico et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
GPCR-targeting nanobodies: attractive research tools, diagnostics, and therapeutics
Azra Mujic-Delic et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2014)
Magnetic antibody-linked nanomatchmakers for therapeutic cell targeting
Ke Cheng et al.
NATURE COMMUNICATIONS (2014)
IgG-Enzyme Fusion Protein: Pharmacokinetics and Anti-Drug Antibody Response in Rhesus Monkeys
Ruben J. Boado et al.
BIOCONJUGATE CHEMISTRY (2013)
Blood-Brain Barrier Molecular Trojan Horse Enables Imaging of Brain Uptake of Radioiodinated Recombinant Protein in the Rhesus Monkey
Ruben J. Boado et al.
BIOCONJUGATE CHEMISTRY (2013)
Potent Immunomodulatory Effects of the Trifunctional Antibody Catumaxomab
Diane Goere et al.
CANCER RESEARCH (2013)
Atypical Antigen Recognition Mode of a Shark Immunoglobulin New Antigen Receptor (IgNAR) Variable Domain Characterized by Humanization and Structural Analysis
Oleg V. Kovalenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Development of a Human IgG4 Bispecific Antibody for Dual Targeting of Interleukin-4 (IL-4) and Interleukin-13 (IL-13) Cytokines
Christoph Spiess et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
CDR-restricted engineering of native human scFvs creates highly stable and soluble bifunctional antibodies for subcutaneous delivery
Brian J. Fennell et al.
MABS (2013)
Improving biophysical properties of a bispecific antibody scaffold to aid developability Quality by molecular design
Thomas Spreter Von Kreudenstein et al.
MABS (2013)
Structure reveals function of the dual variable domain immunoglobulin (DVD-Ig™) molecule
Clarissa G. Jakob et al.
MABS (2013)
Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity
Zenjiro Sampei et al.
PLOS ONE (2013)
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange
Aran F. Labrijn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Directed evolution of Her2/neu-binding IgG1-Fc for improved stability and resistance to aggregation by using yeast surface display
Michael W. Traxlmayr et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2013)
Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier
Jessica A. Couch et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Recombinant antibody mixtures: Production strategies and cost considerations
Soren K. Rasmussen et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity
Juergen Hess et al.
FUTURE ONCOLOGY (2012)
RECRUIT-TandAbs®: harnessing the immune system to kill cancer cells
Fionnuala McAleese et al.
FUTURE ONCOLOGY (2012)
Complexities of TGF-β Targeted Cancer Therapy
Erin C. Connolly et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Molecular Imprint of Enzyme Active Site by Camel Nanobodies RAPID AND EFFICIENT APPROACH TO PRODUCE ABZYMES WITH ALLIINASE ACTIVITY
Jiang-Wei Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain
Mischa R. Mueller et al.
MABS (2012)
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
Takehisa Kitazawa et al.
NATURE MEDICINE (2012)
Non-Agonistic Bivalent Antibodies That Promote c-MET Degradation and Inhibit Tumor Growth and Others Specific for Tumor Related c-MET
Sameer A. Greenall et al.
PLOS ONE (2012)
The MET oncogene as a therapeutical target in cancer invasive growth
Paolo Luraghi et al.
FRONTIERS IN PHARMACOLOGY (2012)
Development of Tetravalent, Bispecific CCR5 Antibodies with Antiviral Activity against CCR5 Monoclonal Antibody-Resistant HIV-1 Strains
Juergen Schanzer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma
Paul A. Moore et al.
BLOOD (2011)
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth
Rob C. Roovers et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Stabilization of the Single-Chain Fragment Variable by an Interdomain Disulfide Bond and Its Effect on Antibody Affinity
Jian-Xin Zhao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2011)
Pathogenic and Protective Functions of TNF in Neuroinflammation Are Defined by Its Expression in T Lymphocytes and Myeloid Cells
Andrey A. Kruglov et al.
JOURNAL OF IMMUNOLOGY (2011)
Reversal of Lysosomal Storage in Brain of Adult MPS-I Mice with Intravenous Trojan Horse-Iduronidase Fusion Protein
Ruben J. Boado et al.
MOLECULAR PHARMACEUTICS (2011)
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
Gregory L. Moore et al.
MABS (2011)
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
Wolfgang Schaefer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Retargeting of T Cells to Prostate Stem Cell Antigen Expressing Tumor Cells: Comparison of Different Antibody Formats
Anja Feldmann et al.
PROSTATE (2011)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls
Leia C. R. Silva et al.
IMMUNOTHERAPY (2010)
Development of a Two-part Strategy to Identify a Therapeutic Human Bispecific Antibody That Inhibits IgE Receptor Signaling
Janet Jackman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects APPLICATIONS TO BISPECIFIC MOLECULES AND MONOVALENT IgG
Kannan Gunasekaran et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Therapeutic approaches for neuronopathic lysosomal storage disorders
Raphael Schiffmann
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
The VEGF family in cancer and antibody-based strategies for their inhibition
Laura A. Sullivan et al.
MABS (2010)
Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions
Gregory L. Moore et al.
MABS (2010)
The immunogenicity of humanized and fully human antibodies Residual immunogenicity resides in the CDR regions
Fiona A. Harding et al.
MABS (2010)
Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties
G. Wozniak-Knopp et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Stability engineering of scFvs for the development of bispecific and multivalent antibodies
Brian R. Miller et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2010)
Remodeling domain interfaces to enhance heterodimer formation
Zhenping Zhu et al.
PROTEIN SCIENCE (2010)
General Strategy to Humanize a Camelid Single-domain Antibody and Identification of a Universal Humanized Nanobody Scaffold
Cecile Vincke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
A bispecific single-chain antibody that mediates target cell-restricted, supra-agonistic CD28 stimulation and killing of lymphoma cells
T. Otz et al.
LEUKEMIA (2009)
Autoimmune diseases induced by TNF-targeted therapies
Manuel Ramos-Casals et al.
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2008)
Interaction of Human C1q with IgG and IgM: Revisited
Mihaela G. Gadjeva et al.
BIOCHEMISTRY (2008)
Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities
Akito Natsume et al.
CANCER RESEARCH (2008)
Central nervous system therapy for lysosomal storage disorders
Gregory M. Enns et al.
NEUROSURGICAL FOCUS (2008)
Distinct structural and adhesive roles of Ca2+ in membrane binding of blood coagulation factors
Y. Zenrnei Ohkubo et al.
STRUCTURE (2008)
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
Chengbin Wu et al.
NATURE BIOTECHNOLOGY (2007)
Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating fcγ receptors
Jeffrey B. Stavenhagen et al.
CANCER RESEARCH (2007)
A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects
Scott E. Strome et al.
ONCOLOGIST (2007)
Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics
Jennifer A. MacDiarmid et al.
CANCER CELL (2007)
CD19/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
Michael Molhoj et al.
MOLECULAR IMMUNOLOGY (2007)
Engineered antibody Fc variants with enhanced effector function
GA Lazar et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A revival of bispecific antibodies
P Kufer et al.
TRENDS IN BIOTECHNOLOGY (2004)
Alternatively spliced isoforms of fibronectin in immune-mediated glomerulosclerosis:: the role of TGFβ and IL-4
HJ Baelde et al.
JOURNAL OF PATHOLOGY (2004)
Contributions of CDR3 to VHH domain stability and the design of monobody scaffolds for naive antibody libraries
CJ Bond et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs inVL-to-VH orientation:: Implications for diabody flexibility
JA Carmichael et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Pretargeting for cancer radioimmunotherapy with bispecific antibodies: Role of the bispecific antibody's valency for the tumor target antigen
H Karacay et al.
BIOCONJUGATE CHEMISTRY (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Optimal design features of camelized human single-domain antibody libraries
J Tanha et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity
AM McCall et al.
JOURNAL OF IMMUNOLOGY (2001)
High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Bispecific human IgG by design
P Carter
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc
EE Idusogie et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
